Etanercept Clearance during an in vitro Model of Continuous Venovenous Hemofiltration | Zendy

Geoffrey M. Fleming | Zendy; Noha N. Salama | Zendy; Saada Eid | Zendy; Kenneth R. Cooke | Zendy; Bruce A. Mueller | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Etanercept Clearance during an in vitro Model of Continuous Venovenous Hemofiltration

Author(s) -

Geoffrey M. Fleming,

Noha N. Salama,

Saada Eid,

Kenneth R. Cooke,

Bruce A. Mueller

Publication year - 2009

Publication title -

blood purification

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.686

H-Index - 57

eISSN - 1421-9735

pISSN - 0253-5068

DOI - 10.1159/000232936

Subject(s) - hemofiltration , etanercept , ultrafiltration (renal) , polysulfone , clearance , renal function , chemistry , urea , chromatography , polyacrylonitrile , medicine , pharmacology , tumor necrosis factor alpha , urology , hemodialysis , surgery , membrane , biochemistry , organic chemistry , polymer

Etanercept is a tumor necrosis factor-alpha antagonist used in inflammation-mediated conditions. Continuous venovenous hemofiltration (CVVH) has also been used in patients with inflammatory conditions. This study evaluated etanercept clearance using an in vitro CVVH model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research